Computational Drug Repositioning for the Identification of New Agents to Sensitize Drug-resistant Breast Tumors Across Treatments and Receptor Subtypes

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jun 29

PMID 37384294

Authors

Katharine Yu

Amrita Basu

Christina Yau

Denise M Wolf

Hani Goodarzi

Sourav Bandyopadhyay

James E Korkola

Gillian L Hirst

Smita Asare

Angela DeMichele

Nola Hylton

Douglas Yee

Laura Esserman

Laura van t Veer

Marina Sirota

Affiliations

Soon will be listed here.

Abstract

Introduction: Drug resistance is a major obstacle in cancer treatment and can involve a variety of different factors. Identifying effective therapies for drug resistant tumors is integral for improving patient outcomes.

Methods: In this study, we applied a computational drug repositioning approach to identify potential agents to sensitize primary drug resistant breast cancers. We extracted drug resistance profiles from the I-SPY 2 TRIAL, a neoadjuvant trial for early stage breast cancer, by comparing gene expression profiles of responder and non-responder patients stratified into treatments within HR/HER2 receptor subtypes, yielding 17 treatment-subtype pairs. We then used a rank-based pattern-matching strategy to identify compounds in the Connectivity Map, a database of cell line derived drug perturbation profiles, that can reverse these signatures in a breast cancer cell line. We hypothesize that reversing these drug resistance signatures will sensitize tumors to treatment and prolong survival.

Results: We found that few individual genes are shared among the drug resistance profiles of different agents. At the pathway level, however, we found enrichment of immune pathways in the responders in 8 treatments within the HR+HER2+, HR+HER2-, and HR-HER2- receptor subtypes. We also found enrichment of estrogen response pathways in the non-responders in 10 treatments primarily within the hormone receptor positive subtypes. Although most of our drug predictions are unique to treatment arms and receptor subtypes, our drug repositioning pipeline identified the estrogen receptor antagonist fulvestrant as a compound that can potentially reverse resistance across 13/17 of the treatments and receptor subtypes including HR+ and triple negative. While fulvestrant showed limited efficacy when tested in a panel of 5 paclitaxel resistant breast cancer cell lines, it did increase drug response in combination with paclitaxel in HCC-1937, a triple negative breast cancer cell line.

Conclusion: We applied a computational drug repurposing approach to identify potential agents to sensitize drug resistant breast cancers in the I-SPY 2 TRIAL. We identified fulvestrant as a potential drug hit and showed that it increased response in a paclitaxel-resistant triple negative breast cancer cell line, HCC-1937, when treated in combination with paclitaxel.

References

Okabe M, Szakacs G, Reimers M, Suzuki T, Hall M, Abe T . Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther. 2008; 7(9):3081-91. PMC: 2597359. DOI: 10.1158/1535-7163.MCT-08-0539. View

Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y . Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res. 2005; 11(16):6030-9. DOI: 10.1158/1078-0432.CCR-04-2671. View

Mittal D, Caramia F, Michiels S, Joensuu H, Kellokumpu-Lehtinen P, Sotiriou C . Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. Cancer Res. 2016; 76(2):264-74. DOI: 10.1158/0008-5472.CAN-15-1567. View

Zhang Y, Tian J, Qu C, Peng Y, Lei J, Li K . Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells. Breast Cancer. 2021; 28(4):859-873. PMC: 8213666. DOI: 10.1007/s12282-021-01221-4. View

Yeh C, Wu A, Chang P, Chen K, Yang C, Yang S . Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med. 2012; 186(11):1180-8. DOI: 10.1164/rccm.201207-1180OC. View

Zhang J, Hu J, Li W, Zhang C, Su P, Wang Y . Rapamycin Antagonizes BCRP-Mediated Drug Resistance Through the PI3K/Akt/mTOR Signaling Pathway in mPRα-Positive Breast Cancer. Front Oncol. 2021; 11:608570. PMC: 8071953. DOI: 10.3389/fonc.2021.608570. View

Chen B, Ma L, Paik H, Sirota M, Wei W, Chua M . Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets. Nat Commun. 2017; 8:16022. PMC: 5510182. DOI: 10.1038/ncomms16022. View

Wang Y, Gao Y, Cheng H, Yang G, Tan W . Stanniocalcin 2 promotes cell proliferation and cisplatin resistance in cervical cancer. Biochem Biophys Res Commun. 2015; 466(3):362-8. DOI: 10.1016/j.bbrc.2015.09.029. View

Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov J, Tamayo P . The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2016; 1(6):417-425. PMC: 4707969. DOI: 10.1016/j.cels.2015.12.004. View

10.

Zhou Y, Zhao R, Tseng K, Li K, Lu Z, Liu Y . Sirolimus induces apoptosis and reverses multidrug resistance in human osteosarcoma cells in vitro via increasing microRNA-34b expression. Acta Pharmacol Sin. 2016; 37(4):519-29. PMC: 4820798. DOI: 10.1038/aps.2015.153. View

11.

Fraser Symmans W, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 25(28):4414-22. DOI: 10.1200/JCO.2007.10.6823. View

12.

Wolf D, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher R, Lee P . Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022; 40(6):609-623.e6. PMC: 9426306. DOI: 10.1016/j.ccell.2022.05.005. View

13.

Chen B, Wei W, Ma L, Yang B, Gill R, Chua M . Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. Gastroenterology. 2017; 152(8):2022-2036. PMC: 5447464. DOI: 10.1053/j.gastro.2017.02.039. View

14.

Spring L, Fell G, Arfe A, Sharma C, Greenup R, Reynolds K . Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020; 26(12):2838-2848. PMC: 7299787. DOI: 10.1158/1078-0432.CCR-19-3492. View

15.

Fiorillo M, Sotgia F, Sisci D, Cappello A, Lisanti M . Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer. Oncotarget. 2017; 8(12):20309-20327. PMC: 5386764. DOI: 10.18632/oncotarget.15852. View

16.

Daemen A, Griffith O, Heiser L, Wang N, Enache O, Sanborn Z . Modeling precision treatment of breast cancer. Genome Biol. 2013; 14(10):R110. PMC: 3937590. DOI: 10.1186/gb-2013-14-10-r110. View

17.

Pommier R, Sanlaville A, Tonon L, Kielbassa J, Thomas E, Ferrari A . Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution. Nat Commun. 2020; 11(1):3431. PMC: 7347884. DOI: 10.1038/s41467-020-17249-7. View

18.

Barker A, Sigman C, Kelloff G, Hylton N, Berry D, Esserman L . I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009; 86(1):97-100. DOI: 10.1038/clpt.2009.68. View

19.

Nanda R, Liu M, Yau C, Shatsky R, Pusztai L, Wallace A . Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020; 6(5):676-684. PMC: 7058271. DOI: 10.1001/jamaoncol.2019.6650. View

20.

Huang Y, Jiang D, Sui M, Wang X, Fan W . Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression. Oncol Rep. 2016; 37(2):705-712. PMC: 5355712. DOI: 10.3892/or.2016.5315. View